1. Ascher-Svanum H, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453–60.
2. Boyer L, et al. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry 2013;13:15.
3. Brissos S, et al. Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res 2008;160:55–62.
4. Emsley R, et al. The evidence for illness progression after relapse in schizophrenia. Schizophr Res 2013;148:117–21.
5. Fleischhacker WW, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res 2014;159:415–20.
6. Hasan A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2–44.
7. Heinrichs DW, et al. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388–98.
8. Jones PB, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079–87.
9. Lambert M, et al. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 2010;12:393–407.
10. Naber D, et al. Aripiprazole once-monthly is superior to paliperidone palmitate in a randomized, head-to-head clinical study. 23. Kongress der European Psychiatric Association (EPA), Wien, 28.–31. März 2015. Poster EPA15–1973.